Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 29
Filtrar
Mais filtros








Intervalo de ano de publicação
1.
Toxicol Appl Pharmacol ; 329: 26-39, 2017 08 15.
Artigo em Inglês | MEDLINE | ID: mdl-28549829

RESUMO

Placental barrier regulates maternal-fetal interchange protecting the baby from damage caused by substances found in the uterine environment or circulating in the vascular system. Organophosphate (OP) pesticides are a paramount group of environmental pollutants used in intensive agriculture for protection against diseases and pests. While many studies have reported an increased risk of pregnancy alterations in pregnant women exposed to OPs, few have analyzed the effects caused by these pesticides in the placenta. Herein, we evaluated the effects of chlorpyrifos (CPF), one of the most widely used OP insecticides, on human placenta using in vitro and ex vivo exposure models. Villous cytotrophoblast cells isolated from normal human term placentas maintained their cell viability, differentiated into syncytiotrophoblast-like structures, and increased the expression of ß-hCG, ABCG2, and P-gp in the presence of CPF at concentrations of 10 to 100µM. The same doses of CPF induced marked changes in chorionic villi samples. Indeed, CPF exposure increased stroma cell apoptosis, altered villi matrix composition, basement membrane thickness, and trophoblastic layer integrity. Histomorphological and ultrastructural alterations are compatible with those found in placentas where maternal-placenta injury is chronic and able to impair the placental barrier function and nutrient transport from mother to the fetus. Our study shows that placental ex vivo exposure to CPF produces tissue alterations and suggest that human placenta is a potential target of CPF toxicity. In addition, it highlights the importance of using different models to assess the effects of a toxic on human placenta.


Assuntos
Clorpirifos/toxicidade , Inibidores da Colinesterase/toxicidade , Vilosidades Coriônicas/efeitos dos fármacos , Inseticidas/toxicidade , Trofoblastos/efeitos dos fármacos , Subfamília B de Transportador de Cassetes de Ligação de ATP/metabolismo , Membro 2 da Subfamília G de Transportadores de Cassetes de Ligação de ATP/metabolismo , Apoptose/efeitos dos fármacos , Membrana Basal/efeitos dos fármacos , Membrana Basal/ultraestrutura , Bioensaio , Diferenciação Celular/efeitos dos fármacos , Células Cultivadas , Gonadotropina Coriônica Humana Subunidade beta/metabolismo , Vilosidades Coriônicas/metabolismo , Vilosidades Coriônicas/ultraestrutura , Relação Dose-Resposta a Droga , Feminino , Humanos , Proteínas de Neoplasias/metabolismo , Gravidez , Reprodutibilidade dos Testes , Medição de Risco , Células Estromais/efeitos dos fármacos , Células Estromais/ultraestrutura , Fatores de Tempo , Técnicas de Cultura de Tecidos , Testes de Toxicidade/métodos , Trofoblastos/metabolismo , Trofoblastos/ultraestrutura
2.
Acta Trop ; 164: 360-368, 2016 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-27686961

RESUMO

American trypanosomiasis has long been a neglected disease endemic in LatinAmerica, but congenital transmission has now spread Chagas disease to cause a global health problem. As the early stages of the infection of placental tissue and the vertical transmission by Trypanosoma cruzi are still not well understood, it is important to investigate the relevance of the first structure of the placental barrier in chorionic villi infection by T. cruzi during the initial stage of the infection. Explants of human chorionic villi from healthy pregnant women at term were denuded of their syncytiotrophoblast and co-cultured for 3h, 24h and 96h with 800,000 trypomastigotes (simulating acute infection). T. cruzi infected cells were identified by immunohistochemistry for cytokeratin-7 (+cytotrophoblast) and CD68 (+macrophages), and the infection was quantified. In placental tissue, the parasite load was analyzed by qPCR and microscopy, and the motile trypomastigotes were quantified in culture supernatant. In denuded chorionic villous, the total area occupied by the parasite (451.23µm2, 1.33%) and parasite load (RQ: 87) was significantly higher (p<0.05) than in the entire villous (control) (5.98µm2, 0.016%) (RQ:1) and with smaller concentration of nitric oxide. Stromal non-macrophage cells were infected as well as cytotrophoblasts and some macrophages, but with significant differences being observed. The parasite quantity in the culture supernatant was significantly higher (p<0.05) in denuded culture explants from 96h of culture. Although the human complete chorionic villi limited the infection, the detachment of the first structure of the placenta barrier (syncytiotrophoblast) increased both the infection of the villous stroma and the living trypomastigotes in the culture supernatant. Therefore structural and functional alterations to chorionic villi placental barrier reduce placental defenses and may contribute to the vertical transmission of Chagas.


Assuntos
Doença de Chagas/transmissão , Vilosidades Coriônicas/parasitologia , Transmissão Vertical de Doenças Infecciosas , Trypanosoma cruzi/metabolismo , Antígenos CD/imunologia , Antígenos de Diferenciação Mielomonocítica/imunologia , Técnicas de Cocultura , Feminino , Humanos , Queratina-7/imunologia , Óxido Nítrico , Placenta/parasitologia , Reação em Cadeia da Polimerase , Gravidez
3.
Vet Immunol Immunopathol ; 157(1-2): 119-23, 2014 Jan 15.
Artigo em Inglês | MEDLINE | ID: mdl-24275040

RESUMO

Chagas' disease, endemic in Latin America, is spread in natural environments through animal reservoirs, including marsupials, mice and guinea pigs. Farms breeding guinea pigs for food are located in some Latin-American countries with consequent risk of digestive infection. The aim of this work was to study the effect of vaccination with Trypanosoma rangeli in guinea pigs challenged with Trypanosoma cruzi. Animals were vaccinated with fixated epimastigotes of T. rangeli, emulsified with saponin. Controls received only PBS. Before being challenged with T. cruzi, parasitemia, survival rates and histological studies were performed. The vaccinated guinea pigs revealed significantly lower parasitemia than controls (p<0.0001-0.01) and a discrete lymphomonocytic infiltrate in cardiac and skeletal muscles was present. In the chronic phase, the histological view was normal. In contrast, control group revealed amastigote nests and typical histopathological alterations compatible with chagasic myocarditis, endocarditis and pericarditis. These results, together with previous works in our laboratory, show that T. rangeli induces immunoprotection in three species of animals: mice, guinea pigs and dogs. The development of vaccines for use in animals, like domestic dogs and guinea pigs in captivity, opens up new opportunities for preventive tools, and could reduce the risk of infection with T. cruzi in the community.


Assuntos
Doença de Chagas/veterinária , Cobaias , Doenças dos Roedores/parasitologia , Trypanosoma cruzi/imunologia , Trypanosoma rangeli/imunologia , Vacinação/veterinária , Animais , Doença de Chagas/imunologia , Doença de Chagas/parasitologia , Doença de Chagas/prevenção & controle , Reservatórios de Doenças/parasitologia , Reservatórios de Doenças/veterinária , Coração/parasitologia , Histocitoquímica/veterinária , Músculo Esquelético/parasitologia , Parasitemia/imunologia , Parasitemia/prevenção & controle , Parasitemia/veterinária , Doenças dos Roedores/imunologia , Doenças dos Roedores/prevenção & controle , Vacinação/métodos
4.
Mem. Inst. Invest. Cienc. Salud (Impr.) ; 10(1): 5-13, jun. 2012. tab, graf
Artigo em Espanhol | LILACS, BDNPAR | ID: lil-663638

RESUMO

Este estudio observacional descriptivo de corte transverso tuvo por objetivo estandarizar una PCR múltiple para la detección simultánea de los genes mecA y pvl en Staphylococcus spp. Se emplearon como cepas control: S. aureus ATCC 25923, S. aureus ATCC 43300 y un aislado de S. aureus portador de los genes mecA y pvl. La extracción de ADN se realizó por el método de ebullición. El límite de detección se estableció por medio de diluciones seriadas de ADN. Se determinó la aplicabilidad de la PCR múltiple testando 41 aislados de S. aureus y 51 Estafilococos coagulasa negativo (ECN) previamente caracterizados por métodos fenotípicos en noviembre del año 2009. Los productos de PCR fueron visualizados por electroforesis en gel de agarosa al 2% previa tinción con bromuro de etidio. Los productos de amplificación de la PCR múltiple presentaron tamaño esperado de 533pb y 433pb para los genes mecA y pvl respectivamente, con límites de detección de hasta 0,5 ng/µL. El gen mecA se detectó en 13 (31,7%) aislados de S. aureus y en 29 (56,7%) ECN. El gen pvl se detectó en 2 (4,9%) S. aureus y no fue detectado en ECN. La presencia del gen mecA tuvo 100% de concordancia con los métodos fenotípicos. Esta técnica es una herramienta útil en la confirmación de cepas de Estafilococos meticilino resistentes e identificación del gen pvl, además de ser relativamente sencilla con la ventaja de detectar ambos genes en una sola reacción


Assuntos
Coagulase , Staphylococcus aureus
5.
Placenta ; 33(4): 264-70, 2012 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-22296856

RESUMO

The aim of the work was to analyze the susceptibility of the placental syncytiotrophoblast (STB) and cytotrophoblast (CTB) cells to infection by the causal agent of congenital Chagas' disease, Trypanosoma cruzi, and the possible parasite route for placental invasion. Monolayers of CTB and STB and VERO as control cells were used. The infection of STB was significantly lower that of the CTB and Vero cells (p < 0.05) which coincided with a significantly increased mortality of parasite cells in the culture medium and trypanocidal levels of nitric oxide. We conclude that the syncytiotrophoblast, the first placental barrier, is the main barrier of the chorionic villous that limits the infection by T. cruzi. This work opens the possibility of a new mechanism for placental infection when there are discontinuities in the first placental barrier.


Assuntos
Doença de Chagas/parasitologia , Trofoblastos/parasitologia , Trypanosoma cruzi/fisiologia , Animais , Células Cultivadas , Doença de Chagas/congênito , Doença de Chagas/patologia , Doença de Chagas/transmissão , Chlorocebus aethiops , Meios de Cultivo Condicionados/metabolismo , Suscetibilidade a Doenças , Feminino , Humanos , Transmissão Vertical de Doenças Infecciosas , Óxido Nítrico/metabolismo , Gravidez , Complicações Parasitárias na Gravidez/parasitologia , Trofoblastos/citologia , Trofoblastos/patologia , Trypanosoma cruzi/crescimento & desenvolvimento , Trypanosoma cruzi/isolamento & purificação , Células Vero
6.
Placenta ; 32 Suppl 2: S90-9, 2011 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-21236487

RESUMO

Workshops are an important part of the IFPA annual meeting. At IFPA Meeting 2010 diverse topics were discussed in twelve themed workshops, six of which are summarized in this report. 1. The placental pathology workshop focused on clinical correlates of placenta accreta/percreta. 2. Mechanisms of regulation of trophoblast invasion and spiral artery remodeling were discussed in the trophoblast invasion workshop. 3. The fetal sex and intrauterine stress workshop explored recent work on placental sex differences and discussed them in the context of whether boys live dangerously in the womb.4. The workshop on parasites addressed inflammatory responses as a sign of interaction between placental tissue and parasites. 5. The decidua and embryonic/fetal loss workshop focused on key regulatory mediators in the decidua, embryo and fetus and how alterations in expression may contribute to different diseases and adverse conditions of pregnancy. 6. The trophoblast differentiation and syncytialisation workshop addressed the regulation of villous cytotrophoblast differentiation and how variations may lead to placental dysfunction and pregnancy complications.


Assuntos
Feto , Placenta , Trofoblastos/fisiologia , Animais , Diferenciação Celular/fisiologia , Fusão Celular , Movimento Celular/fisiologia , Decídua/fisiologia , Decídua/fisiopatologia , Educação , Feminino , Feto/citologia , Feto/parasitologia , Feto/patologia , Feto/fisiologia , Feto/fisiopatologia , Humanos , Masculino , Doenças Parasitárias/imunologia , Doenças Parasitárias/metabolismo , Doenças Parasitárias/patologia , Doenças Parasitárias/fisiopatologia , Placenta/citologia , Placenta/parasitologia , Placenta/patologia , Placenta/fisiologia , Placenta/fisiopatologia , Placenta Acreta/etiologia , Placenta Acreta/metabolismo , Placenta Acreta/patologia , Placenta Acreta/fisiopatologia , Gravidez , Complicações na Gravidez/metabolismo , Complicações na Gravidez/fisiopatologia , Resultado da Gravidez , Caracteres Sexuais , Estresse Fisiológico/fisiologia , Trofoblastos/citologia
7.
Parasitology ; 136(8): 905-18, 2009 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-19523250

RESUMO

Changes in the cardiac beta-adrenergic system in early stages of Trypanosoma cruzi infection have been described. Here, we studied an early (135 days post-infection-p.i.) and a late stage (365 days p.i.) of the cardiac chronic form of the experimental infection (Tulahuen or SGO-Z12 strains), determining plasma epinephrine and norepinephrine levels, beta-receptor density, affinity and function, cardiac cAMP concentration and phosphodiesterase activity, cardiac contractility, and the presence of beta-receptor autoantibodies. Tulahuen-infected mice presented lower epinephrine and norepinephrine levels; lower beta-receptor affinity and density; a diminished norepinephrine response and higher cAMP levels in the early stage, and a basal contractility similar to non-infected controls in the early and augmented in the late stage. The Tulahuen strain induced autoantibodies with weak beta-receptor interaction. SGO-Z12-infected mice presented lower norepinephrine levels and epinephrine levels that diminished with the evolution of the infection; lower beta-receptor affinity and an increased density; unchanged epinephrine and norepinephrine response in the early and a diminished response in the late stage; higher cAMP levels and unchanged basal contractility. The SGO-Z12 isolate induced beta-receptor autoantibodies with strong interaction with the beta-receptors. None of the antibodies, however, acted a as beta-receptor agonist. The present results demonstrate that this system is seriously compromised in the cardiac chronic stage of T. cruzi infection.


Assuntos
Cardiomiopatia Chagásica/fisiopatologia , Receptores Adrenérgicos beta/metabolismo , Trypanosoma cruzi , Agonistas Adrenérgicos beta/sangue , Agonistas Adrenérgicos beta/farmacologia , Animais , Especificidade de Anticorpos , Autoanticorpos/sangue , Autoanticorpos/imunologia , Cardiomiopatia Chagásica/sangue , Cardiomiopatia Chagásica/patologia , Doença Crônica , AMP Cíclico/metabolismo , Epinefrina/sangue , Epinefrina/farmacologia , Coração/efeitos dos fármacos , Coração/fisiopatologia , Camundongos , Contração Miocárdica/efeitos dos fármacos , Miocárdio/metabolismo , Miocárdio/patologia , Norepinefrina/sangue , Norepinefrina/farmacologia , Diester Fosfórico Hidrolases/metabolismo , Receptores Adrenérgicos beta/análise
8.
Exp Parasitol ; 122(3): 218-25, 2009 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-19351532

RESUMO

Biochemical and structural modifications were investigated in axenic cultured Trypanosoma cruzi after treatment with gangliosides. Fluorescence anisotropy showed dose dependent increments in parasite membranes of ganglioside treated epimastigotes. NADP-GDH activity increased in parasites treated at day 4 (13%), 7 (137.2%), and 14 (28.50%) while NAD-MDH but decreased from day 7 to 21 (-5.74%, -32.22%, -27.92%). Treated parasites presented electron-lucent vacuoles opposite to the cytostoma, multilamellar bodies and dilated mitochondrion cristae, disorganized kinetoplast and altered heterochromatin structure. Gangliosides inhibited fusogenic ability (80%) and PLA2 activity (>75%) from the parasite. The same occurred with anti-PLA2 antibodies. Trypomastigotes suffered loss of cytoplasmic material and organelles when GM1 was present in culture medium. We propose that exogenous gangliosides produced: altered lipid order, inhibited membrane enzymes, the parasite energy source shifted from glucose to amino acids, ending on a structural transformation which signals parasite cell death.


Assuntos
Gangliosídeos/farmacologia , Trypanosoma cruzi/efeitos dos fármacos , Animais , Varredura Diferencial de Calorimetria , Adesão Celular/efeitos dos fármacos , Membrana Celular/química , Membrana Celular/efeitos dos fármacos , Membrana Celular/metabolismo , Chlorocebus aethiops , Desidrogenase de Glutamato (NADP+)/análise , Malato Desidrogenase/análise , Microscopia Eletrônica de Transmissão , Proteínas de Protozoários/análise , Proteínas de Protozoários/química , Radiometria , Trypanosoma cruzi/fisiologia , Trypanosoma cruzi/ultraestrutura , Células Vero , Viscosidade/efeitos dos fármacos
9.
Exp Parasitol ; 120(4): 397-402, 2008 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-18848545

RESUMO

The parasite Trypanosoma cruzi is the causative agent of Chagas disease. T. cruzi invasion and replication in cardiomyocytes induce cellular injuries and cytotoxic reactions, with the production of inflammatory cytokines and nitric oxide, both source of reactive oxygen species. The myocyte response to oxidative stress involves the progression of cellular changes primarily targeting mitochondria. We studied the cardiac mitochondrial structure and the enzymatic activity of citrate synthase and respiratory chain CI-CIV complexes, in Albino Swiss mice infected with T. cruzi, Tulahuen strain and SGO Z12 isolate, in two periods of the acute infection. Changes in the mitochondrial structure were detected in both infected groups, reaching values of 71% for Tulahuen and 88% for SGO Z12 infected mice, 30 days post infection. The citrate synthase activity was different according to the evolution of the infection and the parasite strain, but the respiratory chain alterations were similar with either strain.


Assuntos
Doença de Chagas/patologia , Citrato (si)-Sintase/metabolismo , Mitocôndrias Cardíacas/metabolismo , Mitocôndrias Cardíacas/patologia , Complexos Multienzimáticos/metabolismo , Doença Aguda , Animais , Modelos Animais de Doenças , Feminino , Masculino , Camundongos , Mitocôndrias Cardíacas/ultraestrutura , Parasitemia/patologia , Trypanosoma cruzi/classificação , Trypanosoma cruzi/patogenicidade
10.
Placenta ; 29(5): 396-404, 2008 May.
Artigo em Inglês | MEDLINE | ID: mdl-18378304

RESUMO

The StAR-related lipid transfer (START) domain is defined as a motif of around 200 amino acids implicated in lipid/sterol binding. In a previous study, we identified the StarD7 transcript encoding one of the 15 family members with START domain present in the human genome. This transcript was found to be overexpressed in choriocarcinoma JEG-3 cells. In addition, we demonstrated that the recombinant StarD7 protein forms stable Gibbs and Langmuir monolayers at the air-buffer interface, showing marked surface activity and interaction with phospholipid monolayers, mainly with phosphatidylserine, cholesterol and phosphatidylglycerol. This study was undertaken to evaluate the expression and localization of StarD7 protein in trophoblastic samples. Here, we show for the first time the presence of StarD7 protein in human trophoblast cells. Western blot assays revealed a unique specific 34 kDa protein in JEG-3 cell line, choriocarcinoma tissue, complete hydatidiform mole, early and normal term placenta. Immunohistochemical data from early and normal term placentas and complete hydatidiform moles showed that this protein is abundant in the syncytiotrophoblasts, mainly at the apical side of the syncytium, with a weak and focal reaction in the cytotrophoblast cells. Furthermore, an increased StarD7 mRNA and protein expression, as well as a change in its sub-cellular localization was observed in in vitro differentiating cytotrophoblast isolated from normal term placenta. Taken together, these findings support and allow future studies to explore the possibility that StarD7 protein mediates transplacental lipid transport and/or is involved in syncytialization.


Assuntos
Proteínas de Transporte/genética , Proteínas de Transporte/metabolismo , Trofoblastos/metabolismo , Animais , Células COS , Diferenciação Celular/genética , Células Cultivadas , Chlorocebus aethiops , Feminino , Humanos , Mola Hidatiforme/genética , Mola Hidatiforme/metabolismo , Gravidez , Nascimento a Termo/metabolismo , Distribuição Tecidual , Neoplasias Uterinas/genética , Neoplasias Uterinas/metabolismo
11.
Exp Parasitol ; 111(2): 80-6, 2005 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-16085036

RESUMO

The susceptibility of Trypanosoma cruzi strains to nifurtimox and benznidazole has been investigated and resistant strains have been described. Some tricyclic drugs are lethal for trypomastigote and epimastigote forms of T. cruzi (Tulahuen strain) and prevent the disease in mice. We investigated whether clomipramine, a tricyclic antidepressant drug with anti-trypanothione reductase and anti-calmodulin effects, could be effective in treating Albino Swiss mice infected with trypomastigotes of a new T. cruzi isolate from a chronic patient from an endemic area of Argentina in two different treatment schedules. Both treatment schedules were effective in reducing electrocardiographic changes and preventing myocardial structural damage. The cardiac beta-receptors low affinity was compensated for by an increment in their density. This probably maintained cardiac function since 70% of the mice survived for more than 2 years even though anti-cruzipain titers remained high. These results demonstrate that clomipramine, clinically used as a neuroleptic, could be a promising trypanocidal agent for the treatment of Chagas' disease.


Assuntos
Doença de Chagas/tratamento farmacológico , Clomipramina/uso terapêutico , Tripanossomicidas/uso terapêutico , Trypanosoma cruzi/efeitos dos fármacos , Animais , Anticorpos Antiprotozoários/sangue , Antidepressivos Tricíclicos/farmacologia , Antidepressivos Tricíclicos/uso terapêutico , Antígenos de Protozoários/imunologia , Calmodulina/antagonistas & inibidores , Cardiomiopatia Chagásica/parasitologia , Cardiomiopatia Chagásica/prevenção & controle , Doença de Chagas/parasitologia , Doença de Chagas/patologia , Clomipramina/farmacologia , Cisteína Endopeptidases/imunologia , Resistência a Medicamentos , Eletrocardiografia , Humanos , Imunoglobulina G/sangue , Masculino , Camundongos , Miocárdio/metabolismo , Miocárdio/patologia , Parasitemia/tratamento farmacológico , Parasitemia/parasitologia , Proteínas de Protozoários , Receptores Adrenérgicos beta/efeitos dos fármacos , Receptores Adrenérgicos beta/metabolismo , Tripanossomicidas/efeitos adversos , Tripanossomicidas/farmacologia , Trypanosoma cruzi/imunologia , Trypanosoma cruzi/patogenicidade
12.
Exp Parasitol ; 108(3-4): 176-81, 2004.
Artigo em Inglês | MEDLINE | ID: mdl-15582515

RESUMO

UNLABELLED: We hypothesize that a sustained infection of Trypanosoma cruzi into placental tissue might be diminished. Human placental chorionic villi and VERO cells as controls were co-cultured with T. cruzi. Parasites occupied 0.0137% at 3h, 0.0224% (24h), and 0.0572% (72 h) of the total chorionic villi area analyzed and some few placental samples were negative to parasite DNA, whereas 52% of VERO cells were infected at 3h and parasites occupied 0.57%, at 24h the parasite area was of 2.78% and at 72 h was of 3.32%. There were no live parasites in placenta-T. cruzi culture media at 72 h of co-culture. There were significantly increased dead parasites when T. cruzi was treated with unheated culture media coming from placental explants and fewer dead parasites when pre-heated culture media were employed. CONCLUSION: Low productive infection by T. cruzi into placental tissue associated with no viable parasites in the culture media partially due to placental thermo labile substances.


Assuntos
Vilosidades Coriônicas/parasitologia , Trypanosoma cruzi/fisiologia , Animais , Doença de Chagas/transmissão , Chlorocebus aethiops , Técnicas de Cocultura , Feminino , Humanos , Transmissão Vertical de Doenças Infecciosas , Camundongos , Microscopia Eletrônica , Reação em Cadeia da Polimerase , Gravidez , Técnicas de Cultura de Tecidos , Trypanosoma cruzi/ultraestrutura , Células Vero
13.
Int J Antimicrob Agents ; 23(6): 634-6, 2004 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-15194137

RESUMO

Trypanosoma cruzi trypanothione reductase is an enzyme that has been identified as a potential target for chemotherapy. Thioridazine inhibits it and prevented cardiopathy in mice infected with T. cruzi Tulahuen strain. As not all T. cruzi strains respond to treatment in the same way, an isolate from a chronic patient (SGO Z12) was used; parasitaemias were studied along with, survival, serology, electrocardiography, histology and cardiac beta receptor function. Parasitaemia in thioridazine (80 mg/(kg day) for 3 days) treated mice was less and lasted for a shorter period (P < 0.01), there were reduced electrocardiographic and histological alterations and significantly improved survival (80% of non-treated died). Treated mice had lower receptor affinity and higher density as a compensatory mechanism, modifying the course of T. cruzi infection (SGO Z12 isolate) and preventing the consequent cardiopathy.


Assuntos
Cardiomiopatia Chagásica/prevenção & controle , Doença de Chagas/complicações , Doença de Chagas/tratamento farmacológico , Tioridazina/farmacologia , Tioridazina/uso terapêutico , Tripanossomicidas/uso terapêutico , Trypanosoma cruzi/efeitos dos fármacos , Animais , Anticorpos Antiprotozoários/sangue , Modelos Animais de Doenças , Eletrocardiografia , Masculino , Camundongos , Miocárdio/patologia , NADH NADPH Oxirredutases/antagonistas & inibidores , NADH NADPH Oxirredutases/efeitos dos fármacos , Parasitemia , Análise de Sobrevida , Tripanossomicidas/farmacologia
14.
Trans R Soc Trop Med Hyg ; 95(5): 529-33, 2001.
Artigo em Inglês | MEDLINE | ID: mdl-11706667

RESUMO

Trypanosoma cruzi, widely distributed in Latin American countries, provokes Chagas disease, characterized by cardiomyopathy and mega-viscera. The drugs used currently for treatment of acute Chagas disease are highly toxic; the side-effects are undesirable and patients may abandon treatment. We have previously demonstrated that clomipramine (CLO) exerts trypanocidal effects upon epimastigotes and trypomastigotes in vitro with anticalmodulin activity. The present study analyses the effectiveness of CLO treatment in mice infected with a low number of T. cruzi, an animal model that reproduces acute, indeterminate and chronic phases of this trypanosomiasis. In this work, our results demonstrated that CLO 5 mg/kg daily for 30 days, or 2 doses of CLO 40 mg/kg given intraperitoneally at 1 h and 7 days after infection, was not toxic for the host, but was effective against the parasite in that parasitaemias became negative and only mild heart structural and electrocardiographic alterations were detected in the chronic phase in the group treated with CLO 5 mg/kg. In mice treated with CLO 40 mg/kg, none of these alterations was detected. Cardiac beta receptor density and affinity returned to normal in the chronic stage in both experimental groups. T. cruzi enzymes such as calmodulin and trypanothione reductase represent potential drug targets. It has been reported that both can be inhibited by CLO, a tricyclic drug used in clinical therapeutics. We have shown that CLO strongly decreased the mortality rate and electrocardiographic alterations; in addition cardiac beta receptor density and heart histology returned to, or close to, normality 135 days post infection. These results clearly demonstrated that CLO treatment modified significantly the natural evolution of T. cruzi infection.


Assuntos
Antidepressivos Tricíclicos/uso terapêutico , Cardiomiopatia Chagásica/tratamento farmacológico , Clomipramina/uso terapêutico , Animais , Avaliação Pré-Clínica de Medicamentos , Eletrocardiografia , Camundongos , Receptores Adrenérgicos beta/metabolismo , Análise de Sobrevida , Trypanosoma cruzi
15.
Clin Immunol ; 97(2): 89-94, 2000 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-11027448

RESUMO

The R13 peptide sequence (EEEDDDMGFGLFD) that corresponds to the C-terminal region of Trypanosoma cruzi ribosomal P1 and P2 proteins differs from the eukariotic P concensus sequence EESDDDMGFGLFD (H13) only in a nonconservative amino acid substitution. The immunization of BALB/c mice with R13 synthetic peptide coupled to a carrier protein (OVA) induces specific (anti-R13) and autoreactive (anti-H13 and anti-heart) antibodies as well as heart functional alterations. Since aged human and experimental animals are impaired in their responses to most foreign antigens but they produce greater amounts of autoantibodies, in this work we used aged mice as an experimental model able to exaggerate the autoimmune component of the R13-induced response in case it was present. We studied whether these antibodies generated in the absence of the parasite would induce pathological changes in heart tissues. The levels of antibodies against R13 (foreign antigen) and H13 (autoantigen) studied comparatively in 2- and 12-month-old mice 10 days after the third immunization with R13 coupled to OVA were, as we expected for a foreign antigen, higher in almost all sera from 2-month-old mice tested than in sera from 12-month-old mice. Besides, these specific and cross-reactive antibody response remain elevated as long as 150 days post third immunization. In addition, the isotype pattern that recognizes R13 and the self-sequence H13 showed no differences between sera from young and aged mice. Moreover, when ECG traces were obtained from immunized mice, the heart functional alterations observed at 10 days continued at 80 and 150 days after the third immunization, showing an association with the levels of antibodies. In addition, despite the fact that the heart tissue morphology showed no alterations 10 days post third immunization, several abnormalities in the tissue architecture were revealed at 80 and 150 days post third immunization. This report demonstrates the biological relevance of R13-induced cross-reactive antibodies in some of the electrophysiologic and histological changes found in T. cruzi-infected mammalians.


Assuntos
Envelhecimento/fisiologia , Anticorpos Antiprotozoários/imunologia , Coração/fisiologia , Proteínas de Protozoários/imunologia , Proteínas Ribossômicas/imunologia , Animais , Reações Cruzadas/imunologia , Feminino , Camundongos , Camundongos Endogâmicos BALB C , Miocárdio/patologia
16.
Exp Mol Pathol ; 69(2): 144-51, 2000 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-11001862

RESUMO

Five subfractions were collected from six term placentas by mincing and differential centrifugation: homogenate, nuclear, mitochondrial, lysosomal, and supernatant. The effect of each subfraction on Trypanosoma cruzi was assessed by trypan blue exclusion, relative infectivity of mice, and penetration of susceptible cultured VERO cells. Ultrastructural changes in trypomastigotes were identified after high cell mortality was shown by dye exclusion following treatment with lysosomal and supernatant fractions. Trypomastigotes treated with other subfractions or preheated subfractions, those recovered from infected VERO cells, and controls remained unaffected. This was confirmed by the ability of treated trypomastigotes to infect mice or to penetrate susceptible cultured VERO cells. There were a 48% decrease in parasitemia and fewer myocardial lesions in Balb/c mice following treatment with the lysosomal subfraction compared to homogenate and controls. VERO cells were invaded about half as often after lysosomal treatment compared to controls (P < 0. 05); an 11% decrease in cell invasion following homogenate treatment was not significant. Placental lysosomal enzyme activity was unaffected by trypomastigotes. Human placentas contain one or more heat-labile substances in lysosomal and supernatant subfractions which inhibit or injure trypomastigotes of T. cruzi in cell-free systems.


Assuntos
Placenta/imunologia , Placenta/parasitologia , Trypanosoma cruzi/imunologia , Trypanosoma cruzi/patogenicidade , Animais , Doença de Chagas/complicações , Doença de Chagas/congênito , Doença de Chagas/imunologia , Chlorocebus aethiops , Feminino , Humanos , Técnicas In Vitro , Transmissão Vertical de Doenças Infecciosas , Lisossomos/enzimologia , Lisossomos/imunologia , Masculino , Camundongos , Camundongos Endogâmicos BALB C , Microscopia Eletrônica , Gravidez , Complicações Parasitárias na Gravidez/imunologia , Complicações Parasitárias na Gravidez/parasitologia , Trypanosoma cruzi/ultraestrutura , Células Vero
17.
Muscle Nerve ; 23(9): 1407-13, 2000 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-10951444

RESUMO

The goal of the current study was to investigate whether cruzipain, a major Trypanosoma cruzi antigen, is able to induce in mice an autoimmune response and skeletal muscle damage. We demonstrate that immunization with cruzipain triggers immunoglobulin G antibody binding to a 210-kDa antigen from a syngeneic skeletal muscle extract. The absorption of immune sera with purified myosin completely eliminated this reactivity, confirming that the protein identified is really myosin. We also found that spleen cells from immunized mice proliferated in response to a skeletal muscle extract rich in myosin and to purified myosin. Cells from control mice did not proliferate against any of the antigens tested. In addition, we observed an increase in plasma creatine kinase activity, a biochemical marker of muscle damage. Histological studies showed inflammatory infiltrates and myopathic changes in skeletal muscle of immunized animals. Electromyographic studies of these mice revealed changes such as are found in inflammatory or necrotic myopathy. Altogether, our results suggest that this experimental model provides strong evidence for a pathogenic role of anticruzipain immune response in the development of muscle tissue damage.


Assuntos
Autoimunidade/efeitos dos fármacos , Cisteína Endopeptidases/farmacologia , Músculo Esquelético/imunologia , Músculo Esquelético/patologia , Animais , Autoanticorpos/sangue , Autoanticorpos/imunologia , Autoantígenos/imunologia , Creatina Quinase/sangue , Eletromiografia , Feminino , Imunização , Camundongos , Camundongos Endogâmicos BALB C , Monócitos/patologia , Músculo Esquelético/efeitos dos fármacos , Músculo Esquelético/fisiopatologia , Miosinas/imunologia , Miosinas/metabolismo , Proteínas de Protozoários , Baço/imunologia , Baço/patologia
18.
J Parasitol ; 85(5): 970-2, 1999 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-10577739

RESUMO

Adenosine, derived from hydrolysis of 5'-AMP by 5'-nucleotidase activity, may be involved in coupling coronary blood flow to cardiac function and metabolism; it has been postulated as a cardioprotective substance in ischemic myocardium. The stimulation of beta-adrenergic receptors produces an increase in adenosine by 5'-AMP hydrolysis. In addition, it has been demonstrated that in Chagas' disease there is decreased cardiac perfusion. We show in this paper by histochemical and densitometric procedures that ecto-5'-nucleotidase activity increases in ventricles of acutely Trypanosoma cruzi-infected mice and that the density of beta-adrenergic receptors is significantly diminished with affinity similar to controls, showing that a compensatory mechanism was absent. The increase of ecto-5'-nucleotidase in heart myocytes from infected mice may produce cardioprotective adenosine that may be independent of beta-adrenergic function, based on the hypoperfusion conditions of acute chagasic cardiomyopathy.


Assuntos
5'-Nucleotidase/metabolismo , Doença de Chagas/fisiopatologia , Receptores Adrenérgicos beta/metabolismo , Trypanosoma cruzi/enzimologia , Doença Aguda , Adenosina/metabolismo , Animais , Doença de Chagas/enzimologia , Densitometria , Ventrículos do Coração/enzimologia , Ventrículos do Coração/ultraestrutura , Imuno-Histoquímica , Camundongos , Microscopia Eletrônica , Miocárdio/enzimologia
19.
Ann Trop Med Parasitol ; 93(7): 695-702, 1999 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-10715697

RESUMO

Thioridazine, a tricyclic drug, is known to have a direct effect on Trypanosoma cruzi, disrupting the parasites' mitochondria and kinetoplasts. In the present study, the drug was used orally, at 80 mg/kg.day for 3 days, to treat mice inoculated with low numbers of T. cruzi. The drug caused no apparent toxicity in the host. It cleared trypomastigotes from the bloodstream, prevented the histological and functional alterations of the heart normally observed in the chronic phase of the experimental disease, and greatly reduced the mortality rate compared with that in untreated, infected controls. When checked 135 days post-infection, the density of cardiac beta receptors and the cardiac histology of the treated mice were indistinguishable from those of uninfected, untreated controls. The drug is already used to treat humans, as a neuroleptic drug. It appears to be able to prevent acute infection with T. cruzi evolving into chronic disease, at least in mice, and may be a useful base from which to design new agents for the treatment of Chagas disease.


Assuntos
Doença de Chagas/tratamento farmacológico , Tioridazina/uso terapêutico , Tripanossomicidas/uso terapêutico , Trypanosoma cruzi/efeitos dos fármacos , Animais , Doença de Chagas/enzimologia , Avaliação Pré-Clínica de Medicamentos , Camundongos , Tioridazina/administração & dosagem , Tripanossomicidas/administração & dosagem , Trypanosoma cruzi/enzimologia
20.
Ann Trop Med Parasitol ; 93(4): 341-50, 1999 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-10656035

RESUMO

Ganglioside treatment of mice during their acute infection with Trypanosoma cruzi promoted long-term survival and clearance of parasites from the bloodstream and organs. Additionally, such treatment completely prevented the clinical manifestations of the infection, and progression into the chronic stages of the disease, for at least 18 months post-infection. Trypanosoma cruzi must invade nucleated cells to survive and reproduce within the mammalian host, and it has been suggested that ganglioside treatment inhibits the parasite's phospholipase A2 enzymes (PLA2), which are involved in membrane destabilization. However, since total brain gangliosides were not toxic to the parasite, either in xenic or axenic cultures, it seems unlikely that their action in vivo relates to their inhibition of PLA2. Other possible mechanisms of action are discussed.


Assuntos
Doença de Chagas/tratamento farmacológico , Gangliosídeos/uso terapêutico , Doença Aguda , Animais , Técnicas de Cultura de Células , Doença de Chagas/patologia , Camundongos , Miocárdio/patologia , Parasitemia/tratamento farmacológico , Reação em Cadeia da Polimerase , Taxa de Sobrevida , Trypanosoma cruzi/efeitos dos fármacos , Trypanosoma cruzi/crescimento & desenvolvimento
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA